CTY公司概览
盘中时间采用ET。市场数据可能有所延迟。
公司概况
公司网站City Therapeutics, Inc. is a biotechnology company specializing in next-generation RNA interference (RNAi) therapeutics. The company is based in Cambridge, MA. The company engineers potent, specific, and durable RNAi trigger molecules combined with precision targeting ligands to deliver siRNAs beyond the liver to tissues such as ocular and central nervous system targets. Its R&D pipeline includes programs addressing thromboembolic diseases (targeting Factor XI), Stargardt disease (targeting RBP4), and other hepatic, ocular, and CNS conditions. Lead candidates include CITY-FXI, designed to prevent blood clots with reduced bleeding risk, and CITY-RBP4, aimed at slowing or halting vision loss in Stargardt disease. The company was founded by Ari Nowacek, John M. Maraganore. Andrew C. Orth has been the CEO of the company since 2025.
- 行业
- Biotechnology
- 部门
- Healthcare
- 总部
- US
- 上市以来
- 2026年10月16日
- 雇员
- 75
市场位置
日内区间
当前US$22.40
52周区间
当前US$22.40
- 开盘价
- US$21.88
- 前收盘价
- US$18.00
- 成交量
- 140.64万
- 1.53× 平均值
- 平均成交量
- 92.01万
- 日均成交量
- 市值
- 2.18亿 USD
- 贝塔
- 0
- 市场参考 1
- 50天平均值
- US$22.40
- 处于平均水平
- 200天平均值
- US$22.40
- 处于平均水平
